Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin with radiotherapy in newly diagnosed glioblastoma
NCT00509821Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2007
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of enzastaurin in glioblastoma (GBM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression Free Survival at 6 Months. Started Oct 2007; status: completed.
02
Drugs
enzastaurin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00509821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00509821.